Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany

  1. Koehler, Johanna
  2. Ritzer, Barbara
  3. Weidlich, Simon
  4. Gebhardt, Friedemann
  5. Kirchhoff, Chlodwig
  6. Gempt, Jens
  7. Querbach, Christiane
  8. Hoffmann, Dieter
  9. Haller, Bernhard
  10. Schmid, Roland M.
  11. Schneider, Jochen
  12. Spinner, Christoph D.
  13. Iakoubov, Roman ORCID logo

Download
s15010-021-01657-y.pdf 420,57KB
WeightNameValue
1000 Titel
  • Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany
1000 Autor/in
  1. Koehler, Johanna |
  2. Ritzer, Barbara |
  3. Weidlich, Simon |
  4. Gebhardt, Friedemann |
  5. Kirchhoff, Chlodwig |
  6. Gempt, Jens |
  7. Querbach, Christiane |
  8. Hoffmann, Dieter |
  9. Haller, Bernhard |
  10. Schmid, Roland M. |
  11. Schneider, Jochen |
  12. Spinner, Christoph D. |
  13. Iakoubov, Roman |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-07-09
1000 Erschienen in
1000 Quellenangabe
  • 49(6):1313-1318
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s15010-021-01657-y |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269399/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Additional treatment options for coronavirus disease (COVID-19) are urgently needed, particularly for populations at high risk of severe disease. This cross-sectional, retrospective study characterized the outcomes of 43 patients with nosocomial severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection with and without treatment using monoclonal SARS-CoV-2 spike antibodies (bamlanivimab or casirivimab/imdevimab). Our results indicate that treatment with monoclonal antibodies results in a significant decrease in disease progression and mortality when used for asymptomatic patients with early SARS-CoV-2 infection.
1000 Sacherschließung
gnd 1206347392 COVID-19
lokal Imdevimab
lokal SARS-CoV2
lokal Antibodies, Monoclonal/therapeutic use [MeSH]
lokal Humans [MeSH]
lokal Tertiary Care Centers [MeSH]
lokal Retrospective Studies [MeSH]
lokal COVID-19
lokal Cross-Sectional Studies [MeSH]
lokal COVID-19 / SARS-CoV-2
lokal Bamlanivimab
lokal Brief Report
lokal COVID-19 [MeSH]
lokal Casirivimab
lokal Germany [MeSH]
lokal Cross Infection/drug therapy [MeSH]
lokal Monoclonal spike antibodies
lokal SARS-CoV-2 [MeSH]
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/S29laGxlciwgSm9oYW5uYQ==|https://frl.publisso.de/adhoc/uri/Uml0emVyLCBCYXJiYXJh|https://frl.publisso.de/adhoc/uri/V2VpZGxpY2gsIFNpbW9u|https://frl.publisso.de/adhoc/uri/R2ViaGFyZHQsIEZyaWVkZW1hbm4=|https://frl.publisso.de/adhoc/uri/S2lyY2hob2ZmLCBDaGxvZHdpZw==|https://frl.publisso.de/adhoc/uri/R2VtcHQsIEplbnM=|https://frl.publisso.de/adhoc/uri/UXVlcmJhY2gsIENocmlzdGlhbmU=|https://frl.publisso.de/adhoc/uri/SG9mZm1hbm4sIERpZXRlcg==|https://frl.publisso.de/adhoc/uri/SGFsbGVyLCBCZXJuaGFyZA==|https://frl.publisso.de/adhoc/uri/U2NobWlkLCBSb2xhbmQgTS4=|https://frl.publisso.de/adhoc/uri/U2NobmVpZGVyLCBKb2NoZW4=|https://frl.publisso.de/adhoc/uri/U3Bpbm5lciwgQ2hyaXN0b3BoIEQu|https://orcid.org/0000-0003-0952-3986
1000 Hinweis
  • DeepGreen-ID: 1e8723444d4f415ab31b7f477c2a66f1 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6444034.rdf
1000 Erstellt am 2023-04-27T11:45:05.360+0200
1000 Erstellt von 322
1000 beschreibt frl:6444034
1000 Zuletzt bearbeitet Fri Oct 20 11:53:33 CEST 2023
1000 Objekt bearb. Fri Oct 20 11:53:33 CEST 2023
1000 Vgl. frl:6444034
1000 Oai Id
  1. oai:frl.publisso.de:frl:6444034 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source